Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial

Diabetes Care

Volumn 35, Issue 4, 2012, Pages 857-860

  Guyton, John R ^a   Fazio, Sergio ^b   Adewale, Adeniyi J ^c   Jensen, Erin ^c   Tomassini, Joanne E ^c   Shah, Arvind ^c   Tershakovec, Andrew M ^c  

^a DUKE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIDIABETIC AGENT; EZETIMIBE PLUS SIMVASTATIN; GLUCOSE; NICOTINIC ACID;

ADULT; AGED; ARTICLE; CONTROLLED DRUG RELEASE; CONTROLLED STUDY; DIABETES MELLITUS; DOSE RESPONSE; DRUG DOSE INCREASE; DRUG DOSE TITRATION; DRUG EFFECT; DRUG EFFICACY; DRUG SAFETY; DRUG USE; FEMALE; GLUCOSE ASSAY; GLUCOSE BLOOD LEVEL; HUMAN; HYPERLIPIDEMIA; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; REMISSION; RISK BENEFIT ANALYSIS; TREATMENT DURATION; TREATMENT RESPONSE;

ADOLESCENT; ADULT; AGE OF ONSET; AGED; AZETIDINES; DELAYED-ACTION PREPARATIONS; DIABETES COMPLICATIONS; DIABETES MELLITUS; DRUG COMBINATIONS; FEMALE; HUMANS; HYPERLIPIDEMIAS; HYPOLIPIDEMIC AGENTS; MALE; MIDDLE AGED; NIACIN; SIMVASTATIN; TIME FACTORS; YOUNG ADULT;

EID: 84862107330     PISSN: 01495992     EISSN: 19355548     Source Type: Journal    
DOI: 10.2337/dc11-1369     Document Type: Article

References (15)

1. Guyton JR. Niacin in cardiovascular prevention: mechanisms, efficacy, and safety. Curr Opin Lipidol 2007;18:415-420 (Pubitemid 47051920)
2. American Diabetes Association. Diagnosis and classification of diabetes mellitus. Diabetes Care 2011;34(Suppl. 1):S62-S69
3. Guyton JR, Brown BG, Fazio S, Polis A, Tomassini JE, Tershakovec AM. Lipid-altering efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in patients with type IIa or type IIb hyperlipidemia. J Am Coll Cardiol 2008;51:1564-1572 (Pubitemid 351509420)
4. Fazio S, Guyton JR, Polis AB, et al. Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. Am J Cardiol 2010;105:487-494
5. Ford ES, Li CY, Sattar N. Metabolic syndrome and incident diabetes: current state of the evidence. Diabetes Care 2008;31:1898-1904
6. Nathan DM, Davidson MB, DeFronzo RA, et al American Diabetes Association. Impaired fasting glucose and impaired glucose tolerance: implications for care. Diabetes Care 2007;30:753-759 (Pubitemid 46354366)
7. Sampson UK, Linton MF, Fazio S. Are statins diabetogenic? Curr Opin Cardiol 2011;26:342-347
8. Garg A, Grundy SM. Nicotinic acid as therapy for dyslipidemia in non-insulin-dependent diabetes mellitus. JAMA 1990;264:723-726 (Pubitemid 20246864)
9. Coronary Drug Project Research Group. Clofibrate and niacin in coronary heart disease. JAMA 1975;231:360-381
10. Elam MB, Hunninghake DB, Davis KB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: A randomized trial. Arterial Disease Multiple Intervention Trial. JAMA 2000;284:1263-1270
11. Grundy SM, Vega GL, McGovern ME, et al Diabetes Multicenter Research Group. Efficacy, safety, and tolerability of oncedaily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. Arch Intern Med 2002;162:1568-1576 (Pubitemid 34765005)
12. Vega GL, Cater NB, Meguro S, Grundy SM. Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia. Am J Cardiol 2005;95:1309-1313 (Pubitemid 40719861)
13. Rasouli N, Hale T, Kahn SE, Spencer HJ, Elbein SC. Effects of short-term experimental insulin resistance and family history of diabetes on pancreatic beta-cell function in nondiabetic individuals. J Clin Endocrinol Metab 2005;90:5825-5833 (Pubitemid 41415499)
14. Walters RW, Shukla AK, Kovacs JJ, et al. beta-Arrestin1 mediates nicotinic acid-induced flushing, but not its antilipolytic effect, in mice. J Clin Invest 2009;119:1312-1321
15. Lai E, Waters MG, Tata JR, et al. Effects of a niacin receptor partial agonist, MK-0354, on plasma free fatty acids, lipids, and cutaneous flushing in humans. J Clin Lipidol 2008;2:375-383